NeuroSense Therapeutics Ltd.
PrimeC
ALS, Alzheimer’s disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for PrimeC in ALS, Alzheimer’s disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“We are preparing for initiation of a Phase 3 pivotal clinical trial for PrimeC in ALS (PARAGON), following positive Phase 2b PARADIGM results and clearance from the FDA.”